Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
暂无分享,去创建一个
Deepak L. Bhatt | E. Braunwald | B. Scirica | G. Leibowitz | I. Raz | N. Iqbal | K. Ray | B. Hirshberg | Ofri Mosenzon | K. Im | Aliza Rozenberg | Ilan Yanuv | Avivit Cahn | C. Stahre | Cheryl Wei
[1] Akshay S. Desai,et al. Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial , 2016, Diabetes, obesity & metabolism.
[2] J. Hoekman,et al. Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. , 2015, Journal of the American Society of Nephrology : JASN.
[3] Deepak L. Bhatt,et al. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial , 2014, Diabetes Care.
[4] Mark E Molitch,et al. Diabetic Kidney Disease: A Report From an ADA Consensus Conference , 2014, Diabetes Care.
[5] S. Yusuf,et al. Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies , 2014, Diabetologia.
[6] Yuichiro Yamada,et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. , 2014, Kidney international.
[7] G. Bakris,et al. Microalbuminuria as a Risk Predictor in Diabetes: The Continuing Saga , 2014, Diabetes Care.
[8] Yoshiya Tanaka,et al. Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus , 2013, Journal of Diabetes Investigation.
[9] A. Karasik,et al. Urinary Albumin Secretion in Type 2 Diabetes Patients (T2DM) With Albuminuria Treated With Sitagliptin as Add-on Therapy to Metformin: A Real World Data Study , 2014 .
[10] Deepak L. Bhatt,et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.
[11] V. Perkovic,et al. Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction , 2013, Diabetes Care.
[12] A. Hirayama,et al. Association Between Urinary Albumin Excretion and Low-density Lipoprotein Heterogeneity Following Treatment of Type 2 Diabetes Patients with the Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin: A Pilot Study , 2013, American Journal of Cardiovascular Drugs.
[13] Deepak L. Bhatt,et al. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial , 2013, Diabetes/metabolism research and reviews.
[14] S. Nishikawa,et al. Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKCβ Activation in Diabetes , 2012, Diabetes.
[15] K. von Websky,et al. DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy , 2012, Kidney and Blood Pressure Research.
[16] H. Yokomizo,et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. , 2012, Metabolism: clinical and experimental.
[17] Marcello Tonelli,et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study , 2012, The Lancet.
[18] G. Remuzzi,et al. Proteinuria should be used as a surrogate in CKD , 2012, Nature Reviews Nephrology.
[19] S. K. Park,et al. Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats , 2012, Journal of Pharmacology and Experimental Therapeutics.
[20] F. Reis,et al. Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat) , 2011, Experimental diabetes research.
[21] Deepak L. Bhatt,et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. , 2011, American heart journal.
[22] H. Parving,et al. Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria , 2011, Diabetes Care.
[23] S. Hattori. Sitagliptin reduces albuminuria in patients with type 2 diabetes. , 2011, Endocrine journal.
[24] S. Miyamoto,et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes , 2011, Diabetologia.
[25] S. Solomon,et al. Influence of Albuminuria on Cardiovascular Risk in Patients With Stable Coronary Artery Disease , 2007, Circulation.
[26] T. Uzu,et al. Reduction in Microalbuminuria as an Integrated Indicator for Renal and Cardiovascular Risk Reduction in Patients With Type 2 Diabetes , 2007, Diabetes.
[27] D. Drucker,et al. Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.
[28] H. Parving,et al. Microalbuminuria as an early marker for cardiovascular disease. , 2006, Journal of the American Society of Nephrology : JASN.
[29] Rury R Holman,et al. Risk Factors for Renal Dysfunction in Type 2 Diabetes , 2006, Diabetes.
[30] G. Bakris,et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. , 2005, Archives of internal medicine.
[31] S. Adler. Diabetic nephropathy: Linking histology, cell biology, and genetics. , 2004, Kidney international.
[32] Zhongxin Zhang,et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. , 2004, Kidney international.
[33] G. Eknoyan,et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.
[34] Rury R Holman,et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.
[35] S. Yusuf,et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.
[36] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.